| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| P50 | author | Christopher Coyle | Q63642954 |
| P2093 | author name string | C Vale | |
| R E Langley | |||
| F H Cafferty | |||
| P2860 | cites work | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome | Q24246323 |
| Metformin in cancer: translational challenges | Q26866388 | ||
| Metformin and the risk of cancer: time-related biases in observational studies | Q26999266 | ||
| Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis | Q27000727 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies | Q28542914 | ||
| Aggregate data meta-analysis with time-to-event outcomes | Q30742997 | ||
| Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials | Q30982699 | ||
| Effect of metformin on prostate cancer outcomes after radical prostatectomy | Q33551333 | ||
| Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality | Q33668168 | ||
| Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. | Q33718914 | ||
| Understanding the benefit of metformin use in cancer treatment | Q33864199 | ||
| Long-term metformin use is associated with decreased risk of breast cancer. | Q33873130 | ||
| Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials | Q42849516 | ||
| Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial | Q42920181 | ||
| AMPK regulates metabolism and survival in response to ionizing radiation | Q43780269 | ||
| Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response | Q44362277 | ||
| Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy | Q44370016 | ||
| Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes | Q44611165 | ||
| Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis | Q44778970 | ||
| Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study | Q48394963 | ||
| Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. | Q53085995 | ||
| Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. | Q53087215 | ||
| Association of metformin use with cancer incidence and mortality: a meta-analysis. | Q53113408 | ||
| The effect of metformin on mortality following cancer among patients with diabetes. | Q53149555 | ||
| Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. | Q53641389 | ||
| Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. | Q54583667 | ||
| A Cohort Study of Metformin Exposure and Survival in Patients with Stage I-III Colorectal Cancer | Q62516455 | ||
| Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer | Q62774647 | ||
| Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer | Q62774656 | ||
| Repurposing Vitamin D as an Anticancer Drug | Q86596217 | ||
| The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus | Q95383722 | ||
| Accumulating research: a systematic account of how cumulative meta-analyses would have provided knowledge, improved health, reduced harm and saved resources | Q33961015 | ||
| Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders | Q34135248 | ||
| Metformin and breast cancer risk: a meta-analysis and critical literature review | Q34357389 | ||
| Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer | Q34584122 | ||
| The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials | Q34636349 | ||
| The effect of metformin on breast cancer outcomes in patients with type 2 diabetes | Q35000522 | ||
| Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat | Q35006662 | ||
| Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis | Q35125031 | ||
| Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis | Q35202889 | ||
| Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer | Q35511314 | ||
| Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis | Q35558619 | ||
| Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival | Q35586709 | ||
| Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial | Q35627411 | ||
| Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis | Q35842470 | ||
| Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? | Q35909683 | ||
| Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis | Q36051510 | ||
| Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis | Q36478779 | ||
| AMPK, insulin resistance, and the metabolic syndrome | Q36966839 | ||
| Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial | Q37019565 | ||
| Metabolic syndrome, hyperinsulinemia, and colon cancer: a review | Q37081265 | ||
| Association between metformin therapy and mortality after breast cancer: a population-based study | Q37193432 | ||
| Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. | Q37315465 | ||
| The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma | Q37342956 | ||
| Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis | Q37404368 | ||
| Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? | Q37918745 | ||
| Metformin is associated with improved survival in endometrial cancer | Q38165601 | ||
| The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis | Q38181612 | ||
| Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes | Q38268809 | ||
| 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. | Q38417442 | ||
| The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. | Q39140282 | ||
| Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. | Q39944738 | ||
| Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells | Q40050621 | ||
| Metformin and prostate cancer mortality: a meta-analysis. | Q41149937 | ||
| Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy | Q41964435 | ||
| The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus | Q42485644 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| meta-analysis | Q815382 | ||
| neoplasm | Q1216998 | ||
| adjuvant chemotherapy | Q107548221 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 2184-2195 | |
| P577 | publication date | 2016-09-28 | |
| 2016-12-01 | |||
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis | |
| P478 | volume | 27 |
| Q52593454 | A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data integration. |
| Q61806695 | Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers |
| Q50206074 | Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors |
| Q45783993 | Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis |
| Q90481740 | An evolving paradigm of cancer stem cell hierarchies: therapeutic implications |
| Q92541944 | Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction |
| Q37706025 | Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea |
| Q46360731 | Association of Metformin Use and Survival Outcome in Women With Cervical Cancer |
| Q58806129 | Biguanides enhance antifungal activity against Candida glabrata |
| Q64964574 | Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment. |
| Q92723427 | CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation |
| Q59805381 | Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis |
| Q47836759 | Deciphering metabolic rewiring in breast cancer subtypes |
| Q93364919 | Diabetes pharmacotherapy and effects on the musculoskeletal system |
| Q47948290 | Drug repurposing for the treatment of glioblastoma multiforme. |
| Q48229894 | Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor? |
| Q51244733 | Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. |
| Q61813176 | Hypoxic Radioresistance: Can ROS Be the Key to Overcome It? |
| Q36194195 | Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer |
| Q99550121 | Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density |
| Q64113956 | Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responses |
| Q58728819 | Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability |
| Q91826279 | Kinetic modelling of quantitative proteome data predicts metabolic reprogramming of liver cancer |
| Q49908128 | Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models |
| Q47767194 | Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer |
| Q41396184 | Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression. |
| Q97644915 | Metformin Protects ARPE-19 Cells from Glyoxal-Induced Oxidative Stress |
| Q58100848 | Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells |
| Q101051097 | Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma |
| Q90396590 | Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells |
| Q92278973 | Metformin as an adjuvant in breast cancer treatment |
| Q92358221 | Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma |
| Q52331264 | Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. |
| Q47129780 | Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. |
| Q42700292 | Metformin: A Bridge between Diabetes and Prostate Cancer. |
| Q41545473 | Metformin: a review of its potential indications |
| Q41673272 | Obesity and Cancer Metabolism: A Perspective on Interacting Tumor-Intrinsic and Extrinsic Factors |
| Q91000127 | Obesity and cancer treatment efficacy: Existing challenges and opportunities |
| Q64279888 | PYK2 promotes HER2-positive breast cancer invasion |
| Q59793687 | Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue |
| Q64934294 | Personalized medicine in breast cancer: pharmacogenomics approaches. |
| Q59138314 | Pleiotropic Effects of Metformin on Cancer |
| Q39391684 | Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. |
| Q38668187 | Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms |
| Q38674812 | Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors |
| Q38695734 | Repurposing metformin for the prevention of cancer and cancer recurrence |
| Q61799877 | Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study |
| Q41036251 | The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy |
| Q64250611 | The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure |
| Q64104607 | The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances |
| Q57025024 | The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention |
| Q94476055 | The genetic association between type 2 diabetic and hepatocellular carcinomas |
| Q50050991 | The impact of metformin use on the risk of prostate cancer after prostate biopsy in patients with high grade intraepithelial neoplasia |
| Q98613087 | The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence |
| Q41694147 | miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer. |
Search more.